Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 3Sarcoma 1Plasma cell 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1

Interventions

fludarabine phosphate 38Peripheral Blood Stem Cell Transplantation 35Whole-Body Irradiation 30Mycophenolic Acid 29Cyclophosphamide 27Tacrolimus 21Cyclosporine 20Busulfan 17Antilymphocyte Serum 14Methotrexate 13Melphalan 12Sirolimus 9Radiotherapy 8Filgrastim 8Etoposide 8Cyclosporins 8Cord Blood Stem Cell Transplantation 6Transplantation 5Methylprednisolone 5Bortezomib 5sargramostim 4Therapeutics 4Everolimus 4Epoetin Alfa 4Cytarabine 4Carboplatin 4thymoglobulin 3fludarabine 3Thiotepa 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × pirtobrutinib × Plasma cell × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡